|
Antimicrobials
|
DANO MIC (μg/mL)
|
HLJ
|
JL
|
LN
|
SD
|
HN
|
HB
|
YN
|
Resistance (%)
|
Total
|
|---|
|
Norfloxacin
|
≥128
|
27/34
|
26/27
|
24/24
| |
26/27
|
1/1
|
1/1
|
92.11% (105/114)
| |
|
64
|
13/16
|
11/14
|
11/11
| |
10/10
| | |
88.24% (45/51)
| |
|
32
|
9/15
|
8/12
|
10/10
|
1/2
|
6/6
| | |
75.56% (34/45)
| |
|
16
|
1/10
|
1/10
|
1/10
|
7/10
|
3/10
| | |
26% (13/50)
| |
|
8a
|
0/7
|
0/6
|
2/7
| |
0/7
| |
0/2
|
6.9% (2/29)
| |
|
4–0.5
|
4/24
|
0/18
|
2/20
|
1/6
|
0/18
|
0/15
|
0/11
|
6.25% (7/112)
| |
|
≤0.25
|
0/20
|
0/17
|
0/14
|
0/3
|
0/18
|
0/4
|
0/2
|
0 (0/78)
|
43.00% (206/479)
|
|
Ciprofloxacin
|
≥128
|
28/34
|
26/27
|
24/24
| |
26/27
|
1/1
|
1/1
|
92.98% (106/114)
| |
|
64
|
13/16
|
11/14
|
11/11
| |
10/10
| | |
88.24% (45/51)
| |
|
32
|
10/15
|
8/12
|
10/10
|
1/2
|
6/6
| | |
77.78% (35/45)
| |
|
16
|
1/10
|
5/10
|
5/10
|
10/10
|
7/10
| | |
56% (28/50)
| |
|
8a
|
0/7
|
1/6
|
4/7
| |
1/7
| |
0/2
|
20.69% (6/29)
| |
|
4–0.5
|
4/24
|
1/18
|
2/20
|
1/6
|
0/18
|
0/15
|
0/11
|
7.14% (8/112)
| |
|
≤0.25
|
0/20
|
0/17
|
0/14
|
0/3
|
0/18
|
0/4
|
0/2
|
0 (0/78)
|
47.60% (228/479)
|
|
Ofloxacin
|
≥128
|
26/34
|
26/27
|
24/24
| |
26/27
|
1/1
|
1/1
|
91.23% (104/114)
| |
|
64
|
12/16
|
12/14
|
10/11
| |
10/10
| | |
86.27% (44/51)
| |
|
32
|
10/15
|
8/12
|
9/10
|
1/2
|
6/6
| | |
75.56% (34/45)
| |
|
16
|
1/10
|
3/10
|
4/10
|
10/10
|
7/10
| | |
50% (25/50)
| |
|
8a
|
0/7
|
1/6
|
3/7
| |
3/7
| |
0/2
|
24.14% (7/29)
| |
|
4–0.5
|
4/24
|
1/18
|
4/20
|
1/6
|
1/18
|
0/15
|
0/11
|
9.82% (11/112)
| |
|
≤0.25
|
0/20
|
0/17
|
0/14
|
0/3
|
0/18
|
0/4
|
0/2
|
0 (0/78)
|
47.00% (225/479)
|
|
Levofloxacin
|
≥128
|
24/34
|
25/27
|
23/24
| |
26/27
|
1/1
|
1/1
|
87.72% (100/114)
| |
|
64
|
9/16
|
9/14
|
9/11
| |
10/10
| | |
72.55% (37/51)
| |
|
32
|
3/15
|
7/12
|
4/10
|
1/2
|
5/6
| | |
44.44% (20/45)
| |
|
16
|
1/10
|
0/10
|
2/10
|
9/10
|
5/10
| | |
34% (17/50)
| |
|
8a
|
0/7
|
0/6
|
3/7
| |
2/7
| |
0/2
|
17.24% (5/29)
| |
|
4–0.5
|
4/24
|
0/18
|
2/20
|
1/6
|
0/18
|
0/15
|
0/11
|
6.25% (7/112)
| |
|
≤0.25
|
0/20
|
0/17
|
0/14
|
0/3
|
0/18
|
0/4
|
0/2
|
0 (0/78)
|
38.83% (186/479)
|
- Note: DANO Danofloxacin, HLJ Heilongjiang, JL Jilin, LN Liaoning, SD Shandong, HN Henan, HB Hubei, YN Yunan; a, the susceptibility breakpoint of DANO against swine-derived E. coli [5]
